Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,173 | 10,735 | 7,134 | 7,714 | 5,007 |
| TOTAL | $17,198 | $13,484 | $7,974 | $8,302 | $5,222 |
| Non-Current Assets | |||||
| PPE Net | 483 | 316 | 463 | 33 | 23 |
| Intangibles | 11,148 | 11,148 | 11,148 | 11,148 | 11,148 |
| Other Non-Current Assets | 202 | 287 | 0 | 0 | 0 |
| TOTAL | $11,833 | $11,751 | $11,611 | $11,181 | $11,171 |
| Total Assets | $29,031 | $25,235 | $19,585 | $19,483 | $16,393 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 296 |
| Accounts payable and accrued liabilities | 2,920 | 3,570 | 3,698 | 1,712 | 1,049 |
| Other current liabilities | N/A | N/A | 180 | 503 | N/A |
| TOTAL | $2,920 | $3,570 | $3,878 | $2,215 | $1,345 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 8,351 | 6,094 | 1,328 | 0 | 0 |
| TOTAL | $8,351 | $6,094 | $1,435 | $150 | $88 |
| Total Liabilities | $11,271 | $9,664 | $5,313 | $2,365 | $1,433 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 76 | 24 | 13 | 11 | 8 |
| Common Shares | 69 | 46 | 29 | 21 | 12 |
| Retained earnings | -56,916 | -39,561 | -26,356 | -14,480 | -4,675 |
| Other shareholders' equity | -64 | 31 | 35 | 0 | 0 |
| TOTAL | $17,760 | $15,571 | $14,272 | $17,118 | $14,960 |
| Total Liabilities And Equity | $29,031 | $25,235 | $19,585 | $19,483 | $16,393 |